InvestorPlace - Stock Market News, Stock Advice & Trading Tips
One of the best-performing stocks in the market in recent weeks has been Longeveron (NASDAQ:LGVN). Today, LGVN stock is soaring once again, up nearly 80% at the time of writing, on five times the average daily volume of shares.
Among speculative biotech stocks, Longeveron continues to outperform the market by a wide margin. Trading at only $3 per share a week ago, shares of LGVN stock have skyrocketed to more than $30 per share today.
This week-long move was initially inspired by a key update from the Food and Drug Administration (FDA). The FDA approved Longeveron's Lomacel-B drug for a Rare Pediatric Disease (RPD) designation.
This means that the company's clinical trials will accelerate. Based on the data presented, Longeveron's window to bring this drug to market has been reduced. Additionally, other drugs in the company's pipeline could receive priority vouchers to be reviewed within six months, rather than the typical 10 months. For a biotech stock, this is a big deal.
It appears the run-up in this company's stock price is a continuation of this trade. However, for those interested in what Longeveron does, let's dive into a few things to know.
What to Know About LGVN Stock
Longeveron is a clinical-stage biotech company focused on finding therapies for life-threatening conditions.
Indeed, the company's focus on finding regenerative medicine approaches is one investors seem to like.
The company's Lomacel-B drug candidate is among the company's leading prospective drugs.
However, the company has a pipeline of other drugs investors are growing increasingly bullish on.
The aforementioned FDA RPD designation appears to have boosted the value of the company's drug portfolio dramatically.
The timeline to bring drugs to market is a key determining factor of how biotech stocks are valued.
Accordingly, investors seem like like LGVN stock in the context of these recent announcements.
On the date of publication, Chris MacDonald did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
最近几周市场上表现最好的股票之一是Longeveron(纳斯达克：LGVN)今天，LGVN的股票再次飙升，在撰写本文时上涨了近80%，是日均成交量的五倍。
在投机性生物科技股中，Longeveron继续以较大幅度跑赢大盘。一周前，LGVN的股价仅为每股3美元，如今股价已飙升至每股30美元以上。
这一为期一周的举措最初是受到美国食品和药物管理局(FDA)一项关键更新的启发。FDA批准了Longeveron的Lomacel-B药物用于一种罕见的儿科疾病(RPD)。
这意味着该公司的临床试验将会加速。根据提供的数据，隆格韦隆公司将这种药物推向市场的窗口已经减少。此外，该公司正在研发的其他药物可能会获得优先代金券，在6个月内进行审查，而不是通常的10个月。对于一只生物科技股来说，这是一件大事。
看来这家公司股价的上涨是这种交易的延续。然而，对于那些对Longeveron的工作感兴趣的人，让我们深入了解一些事情。
关于LGVN股票应该知道些什么
Longeveron是一家临床阶段的生物技术公司，专注于寻找治疗危及生命的疾病的方法。
事实上，该公司专注于寻找再生医学方法似乎是投资者喜欢的。
该公司的Lomacel-B候选药物是该公司领先的预期药物之一。
然而，该公司还有投资者越来越看好的其他药物的流水线。
前面提到的FDA RPD的指定似乎极大地提高了该公司的药物组合的价值。
将药物推向市场的时间表是生物技术股票估值的关键决定因素。
因此，在最近这些声明的背景下，投资者似乎就像LGVN的股票。
在本文发表之日，克里斯·麦克唐纳(Chris MacDonald)没有(直接或间接)持有本文提到的证券的任何头寸。本文表达的观点是作者的观点，以InvestorPlace.com为准出版指南.
